The Companies That Are Pioneering Complex Copycat Drugs
As patent protections fall, biosimilars gain ground. Meanwhile, companies race to find a cure for a lung-scarring disease.
The San Francisco Business Times:
Politics, Drug Development Merge As Patent Protections Fall And Biosimilars Gain Ground
In opposing corners of the biopharmaceutical world, two very different companies are pursuing a strikingly similar goal: pioneering a new class of complex copycat drugs known as biosimilars. (Heppler, 5/20)
The San Francisco Business Times:
The Killer Disease That Everyone Wants To Kill: How The Battle Against IPF Is Heating Up
The race for a next-generation drug to attack a killer lung-scarring disease could be won in the Bay Area. (Procter, 5/19)